PHApproved#4 in categoryWATCHLIST

UTI Healthcare Fund

UTI MF · Kaushik Basu · benchmarked to Nifty Pharma TRI

Prospera Research Engine unknown · Data as of 1 Jan 1970 · Synced 1 Jan 1970Review date unknown, validation required

Prospera VerdictOn Watchlist

Scored 56.8/100, in the WATCHLIST band. On Prospera's radar, but hasn't cleared the bar for a formal recommendation yet.

Final Score56.8

1Y Return18.3%

3Y CAGR22.7%

5Y CAGR15.5%

AUM₹1.1K Cr

Expense Ratio1.36%

Eligibility: All gates passed

Prospera Research

Score Breakdown

13 weighted parameters, exactly as configured in the Research Engine, 8 qualitative (analyst-scored) plus 5 quantitative (formula-derived), summing to a final score out of 100.

Momentum (7% weight)6.7/10

3–6M price+flow vs benchmark

Consistency (10% weight)7.4/10

3Y/5Y quartile rank stability

Portfolio Quality (11% weight)7.0/10

PE, concentration, churn

Fund Mgr Quality (12% weight)6.0/10

Philosophy, communication, style drift

Valuation Risk (10% weight)5.0/10

Portfolio PE/PB vs category avg

Sector Tailwinds (9% weight)6.0/10

Policy/macro drivers 12-18M

Downside Protection (8% weight)4.0/10

Max DD, Sortino, bear markets

Outperformance Prob. (8% weight)5.0/10

Analyst 12M alpha probability

Mgr Tenure Score (8% weight)6.0/10

Years managing fund → 1-10 score

AMC Quality Score (6% weight)5.0/10

Research depth, AUM scale, compliance

AUM Trend Score (5% weight)6.0/10

Growing=9, Stable=6, Declining=3

Expense Ratio Score (4% weight)1.0/10

Inverse ER — lower cost = higher score

Thesis Strength (2% weight)5.0/10

Analyst 12-24M thesis conviction

Final Score56.8/100

Prospera Research

Analyst Write-Up

A full analyst write-up hasn't been published for this fund yet, only shortlisted funds at the review stage get one. The score breakdown and performance data above are still real and current.

Prospera Research

Risk-Adjusted Performance

3Y AlphaN/A

5Y AlphaN/A

Max Drawdown20.0%

Sharpe (3Y)1.18

Sortino (3Y)1.79

Beta0.70

Alpha Consistency58%